GLP-1 Vision Loss Claims
Vision Loss & GLP-1 Medications
Last updated: November 3, 2026
Studies have linked GLP-1 medications including Ozempic, Wegovy, and Rybelsus to an increased risk of NAION — a serious condition that causes sudden, often permanent vision loss. Federal litigation is now underway.
NAION (non-arteritic anterior ischemic optic neuropathy) causes sudden, often permanent vision loss and has been linked to GLP-1 medications including Ozempic, Wegovy, and Rybelsus. Research published in JAMA Ophthalmology identified a statistically significant association. Vision loss cases are consolidated in MDL 3163 in the Eastern District of Pennsylvania. The larger gastrointestinal MDL 3094 had more than 4,000 claims pending as of October 1, 2026. Attorneys handle these claims on a contingency fee basis — no cost unless you receive compensation.
What Is NAION
NAION (non-arteritic anterior ischemic optic neuropathy) occurs when blood flow to the optic nerve is suddenly disrupted, causing damage to the nerve fibers that carry visual information from the eye to the brain. It is the most common cause of acute optic nerve damage in adults over 50.
Patients with NAION typically experience sudden, painless vision loss in one eye — often noticed upon waking. The vision loss can range from mild blurring or dimming to complete blindness in the affected eye. In some cases, the other eye may also be affected over time. There is currently no proven treatment to restore vision lost to NAION.
NAION can profoundly affect daily life, impacting the ability to drive, read, work, and perform routine tasks. The sudden and often permanent nature of the vision loss makes it a devastating diagnosis.
Link Between GLP-1 Drugs and Vision Loss
Research published in peer-reviewed medical journals has identified a significant association between GLP-1 receptor agonist medications — particularly semaglutide (Ozempic, Wegovy, Rybelsus) — and an increased risk of developing NAION. Studies have shown that patients using these medications may face a substantially higher risk of NAION compared to the general population.
While the exact mechanism is still being studied, researchers believe GLP-1 medications may affect blood flow to the optic nerve, potentially through changes in blood pressure, vascular function, or rapid weight loss. The risk appears to be present across patients using GLP-1 drugs for both diabetes management and weight loss.
Lawsuits allege that the manufacturers of these medications knew or should have known about the vision loss risk and failed to adequately warn patients and prescribing physicians, depriving them of the ability to make informed decisions about their treatment.
Other Qualifying GLP-1 Injuries
In addition to vision loss, the following injuries related to GLP-1 medications are included in the current litigation:
Gastroparesis
Stomach paralysis causing severe nausea, vomiting, bloating, and inability to digest food normally. May require hospitalization or surgery.
Learn moreBowel Obstruction
A blockage in the intestines preventing food and fluids from passing. A medical emergency that may require surgery.
Learn morePancreatitis
Inflammation of the pancreas causing severe abdominal pain, nausea, and vomiting. Can be life-threatening in severe cases.
Learn moreGallbladder Disease
Gallstones and gallbladder inflammation linked to GLP-1 medications, often requiring surgical removal of the gallbladder.
Learn moreCurrent Litigation Status
Vision loss claims against GLP-1 drug manufacturers have been consolidated in MDL 3163 (In Re: Glucagon-Like Peptide-1 Receptor Agonists [GLP-1 RAs] Vision Injury Products Liability Litigation) in the Eastern District of Pennsylvania.
New cases continue to be filed. This MDL is separate from the larger gastrointestinal injury litigation (MDL 3094), reflecting the distinct nature of the vision loss injuries.
The litigation is in its early stages. As scientific evidence continues to emerge and more affected patients come forward, the number of cases is expected to grow. No settlements have been reached yet, and bellwether trial scheduling is still being determined.
Do You Qualify?
You may be eligible to file a GLP-1 vision loss claim if the following apply:
Used a GLP-1 Medication
You were prescribed and used Ozempic, Wegovy, Rybelsus, Mounjaro, or another GLP-1 receptor agonist medication.
Diagnosed with NAION
You were diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) or experienced sudden, unexplained vision loss after starting the medication.
Ophthalmologist Confirmation
Your vision loss was evaluated and documented by an ophthalmologist or neuro-ophthalmologist, providing medical evidence of NAION or optic nerve damage.
Not Already Represented
You are not currently represented by another attorney for this specific claim.
Frequently Asked Questions
What is NAION?
NAION (non-arteritic anterior ischemic optic neuropathy) is a condition caused by reduced blood flow to the optic nerve, resulting in sudden, painless vision loss in one eye. It is the most common cause of acute optic nerve damage in adults over 50. Vision loss from NAION is often permanent and can range from mild blurring to complete blindness in the affected eye.
How are GLP-1 medications linked to vision loss?
Studies have found that patients using semaglutide-based medications (Ozempic, Wegovy, Rybelsus) have a significantly elevated risk of developing NAION compared to the general population. Researchers believe the drugs may affect blood flow to the optic nerve, though the exact mechanism is still being studied. The FDA and medical community have flagged this association, and litigation is now underway.
Which GLP-1 drugs are linked to NAION?
The strongest evidence currently links semaglutide-based medications — Ozempic, Wegovy, and Rybelsus — to NAION. However, other GLP-1 receptor agonists including Mounjaro, Saxenda, and Trulicity may also carry similar risks. The litigation is still in its early stages, and the scope of included medications may expand as more evidence emerges.
What is the status of the vision loss litigation?
Vision loss cases are consolidated in MDL 3163 in the Eastern District of Pennsylvania. The larger gastrointestinal MDL 3094 had more than 4,000 claims pending as of October 1, 2026. This litigation is in its early stages and is separate from the larger gastrointestinal injury MDL. As more cases are filed and evidence is gathered, the litigation is expected to grow.
What does it cost to file a claim?
There is no cost to you. Attorneys handling GLP-1 vision loss cases work on a contingency fee basis, meaning they only get paid if you receive compensation. NuLegal's initial case review is completely free with no obligation.
Vision Loss Claims by State
Filing deadlines and procedures vary by state. Select your state for specific legal information about GLP-1 vision loss claims.
Alabama
Injury 2 years · Product 2 years
Alaska
Injury 2 years · Product 2 years
Arizona
Injury 2 years · Product 2 years
Arkansas
Injury 3 years · Product 3 years
California
Injury 2 years · Product 2 years
Colorado
Injury 2 years · Product 2 years
Connecticut
Injury 2 years · Product 3 years
Delaware
Injury 2 years · Product 2 years
District of Columbia
Injury 3 years · Product 3 years
Florida
Injury 2 years · Product 4 years
Georgia
Injury 2 years · Product 2 years
Hawaii
Injury 2 years · Product 2 years
Idaho
Injury 2 years · Product 2 years
Illinois
Injury 2 years · Product 2 years
Indiana
Injury 2 years · Product 2 years
Iowa
Injury 2 years · Product 2 years
Kansas
Injury 2 years · Product 2 years
Kentucky
Injury 1 year · Product 1 year
Louisiana
Injury 2 years · Product 2 years 1 year if injured before July 1, 2024
Maine
Injury 6 years · Product 6 years
Maryland
Injury 3 years · Product 3 years
Massachusetts
Injury 3 years · Product 3 years
Michigan
Injury 3 years · Product 3 years
Minnesota
Injury 6 years · Product 4 years
Mississippi
Injury 3 years · Product 3 years
Missouri
Injury 5 years · Product 5 years
Montana
Injury 3 years · Product 3 years
Nebraska
Injury 4 years · Product 4 years
Nevada
Injury 2 years · Product 2 years
New Hampshire
Injury 3 years · Product 3 years
New Jersey
Injury 2 years · Product 2 years
New Mexico
Injury 3 years · Product 3 years
New York
Injury 3 years · Product 3 years
North Carolina
Injury 3 years · Product 3 years
North Dakota
Injury 6 years · Product 6 years
Ohio
Injury 2 years · Product 2 years
Oklahoma
Injury 2 years · Product 2 years
Oregon
Injury 2 years · Product 2 years
Pennsylvania
Injury 2 years · Product 2 years
Rhode Island
Injury 3 years · Product 3 years
South Carolina
Injury 3 years · Product 3 years
South Dakota
Injury 3 years · Product 3 years
Tennessee
Injury 1 year · Product 1 year
Texas
Injury 2 years · Product 2 years
Utah
Injury 4 years · Product 2 years
Vermont
Injury 3 years · Product 3 years
Virginia
Injury 2 years · Product 2 years
Washington
Injury 3 years · Product 3 years
West Virginia
Injury 2 years · Product 2 years
Wisconsin
Injury 3 years · Product 3 years
Wyoming
Injury 4 years · Product 4 years
Don't Wait
Statutes of limitations may limit how long you have to file. Get a free, no-obligation case review today to find out if you qualify for compensation.
Free Case ReviewAdvertisement
Disclosure: NuLegal operates as a legal referral service. Attorney Ashkaan Hassan evaluates claims and refers qualified cases to specialized trial firms, earning a referral fee from the attorney's share of any recovery. Clients never pay out of pocket.